{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:48:28Z","timestamp":1792104508723,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"DOI":"10.1007\/s00115-026-02027-5","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:18:18Z","timestamp":1792102698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetische Varianz in den Genen CYP2D6 und CYP2C19: Relevanz f\u00fcr die Behandlung von Depressionen","Genetic Variation in the CYP2D6 and CYP2C19 Genes: Relevance for the Treatment of Depression"],"prefix":"10.1007","author":[{"given":"Maike","family":"Scherf-Clavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Hampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"1","key":"2027_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman\u00a0CA, Stevenson\u00a0JM, Ramsey\u00a0LB et\u00a0al (2023) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther 114(1):51\u201368","journal-title":"Clin Pharmacol Ther"},{"key":"2027_CR2","doi-asserted-by":"publisher","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2022) Nationale VersorgungsLeitlinie Unipolare Depression \u2013 Kurzfassung, Version\u00a03.2.. Zugegriffen: 1. Febr. 2025. https:\/\/doi.org\/10.6101\/AZQ\/000506","DOI":"10.6101\/AZQ\/000506"},{"key":"2027_CR3","doi-asserted-by":"crossref","unstructured":"Gaebler AJ, Schneider KL, Stingl JC, Paulzen M (2020) Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1\/*17 genotype suggesting a rapid metabolizer status. Pharmacogenomics\u00a0J 20(6):840\u2013844","DOI":"10.1038\/s41397-020-0169-y"},{"issue":"5","key":"2027_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00115-008-2471-9","volume":"79","author":"E Haen","year":"2008","unstructured":"Haen\u00a0E, Greiner\u00a0C, Bader\u00a0W et\u00a0al (2008) Expanding therapeutic reference ranges using dose-related reference ranges. Nervenarzt 79(5):558\u2013566","journal-title":"Nervenarzt"},{"key":"2027_CR5","doi-asserted-by":"publisher","DOI":"10.1055\/a-2860-7861","author":"X Hart","year":"2026","unstructured":"Hart\u00a0X, Gr\u00fcnder\u00a0G, Hiemke\u00a0C et\u00a0al (2026) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects. Pharmacopsychiatry. https:\/\/doi.org\/10.1055\/a-2860-7861 (Online im Druck)","journal-title":"Pharmacopsychiatry"},{"key":"2027_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00115-017-0479-8","volume":"89","author":"D M\u00fcller","year":"2018","unstructured":"M\u00fcller\u00a0D, Brandl\u00a0DJ, Degenhardt\u00a0F et\u00a0al (2018) Pharmakogenetik in der Psychiatrie: Eine Standortbestimmung. Nervenarzt 89:290\u2013299","journal-title":"Nervenarzt"},{"issue":"2","key":"2027_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00702-024-02819-6","volume":"132","author":"J Riegger","year":"2025","unstructured":"Riegger\u00a0J, Egberts\u00a0KM, Clement\u00a0HW et\u00a0al (2025) Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance study. J\u00a0Neural Transm 132(2):295\u2013312","journal-title":"J Neural Transm"},{"key":"2027_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s00103-022-03559-2","volume":"65","author":"RKI","year":"2022","unstructured":"RKI (2022) Richtlinie der Gendiagnostik-Kommission (GEKO) f\u00fcr die Beurteilung genetischer Eigenschaften hinsichtlich ihrer Bedeutung f\u00fcr die Wirkung eines Arzneimittels bei einer Behandlung gem\u00e4\u00df \u00a7\u00a023 Abs.\u00a02 Nr.\u00a01b GenDG. Bundesgesundheitsbl 65:958\u2013962","journal-title":"Bundesgesundheitsbl"},{"issue":"4","key":"2027_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/15622975.2024.2321553","volume":"25","author":"M Scherf-Clavel","year":"2024","unstructured":"Scherf-Clavel\u00a0M, Weber\u00a0H, Unterecker\u00a0S et\u00a0al (2024b) Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders. World J Biol Psychiatry 25(4):214\u2013221","journal-title":"World J Biol Psychiatry"},{"issue":"8","key":"2027_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/02698811251337387","volume":"39","author":"M Scherf-Clavel","year":"2025","unstructured":"Scherf-Clavel\u00a0M, Weber\u00a0H, Wei\u00df\u00a0C et\u00a0al (2025) CYP1A2 genotype-dependent effects of smoking on mirtazapine serum concentrations. Psychopharmacol 39(8):847\u2013854","journal-title":"Psychopharmacol"},{"issue":"7-9","key":"2027_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14622416.2025.2541402","volume":"26","author":"E Tavakoli","year":"2025","unstructured":"Tavakoli\u00a0E, Magarbeh\u00a0L, Elsheikh\u00a0S et\u00a0al (2025) Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review. Pharmacogenomics 26(7-9):295\u2013309","journal-title":"Pharmacogenomics"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02027-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:18:20Z","timestamp":1792102700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02027-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":11,"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-02027-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Scherf-Clavel erhielt Beraterhonorare von Rovi. S.\u00a0Unterecker erhielt Referentenhonorar und Fortbildungskostenunterst\u00fctzung durch Rovi und Johnson&Johnson. H.\u00a0Weber, C.\u00a0Hampf, D.\u00a0M\u00fcller, S.\u00a0Walther und J.\u00a0Deckert geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}